Rapport says new-mechanism drug RAP-219 met goal in phase 2 bipolar mania trial
Rapport Therapeutics says RAP-219 beat placebo by 3.1 points on the Young Mania Rating Scale at three weeks in a 253-patient phase 2 trial, with no serious adverse events but more dropouts for side effects.